Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine
reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied
in the development program for the treatment of major depressive disorder (MDD), for
vasomotor symptoms (VMS) associated with menopause, and for pain associated with peripheral
diabetic neuropathy, as well as for the treatment of fibromyalgia syndrome. This study will
investigate the safety, efficacy, and tolerability of DVS SR in women with MDD who are peri-
and postmenopausal.